Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease.

Background: This research aims to investigate the influence of environmental factors on the treatment efficacy of ocular lubricants in patients from urban areas with dry eye disease (DED).
Methods: A phase IV clinical trial, which included 173 patients from major cities in Mexico, was randomly assigned to use ocular lubricants four times a day for 30 days. Ocular Surface Disease Index (OSDI), noninvasive tear film break-up time (NIBUT), ocular staining, and conjunctival hyperemia (CH) among other factors like weather, and air pollution as covariates were analysed.
Results: After 30 days, OSDI score decreased by 14.8 points ( p <0.001), and NIBUT increased by 2.9 seconds ( p < 0.001), with longer values observed in patients recruited in autumn and winter (additional 1.8 seconds, p < 0.05) compared to those recruited in spring. Patients living in cities with cooler weather and high humidity, but low air quality had higher OSDI and conjunctival stain scores of up to 4.4 and 0.3 points, respectively, as compared to those living in cities with similar pollution and humidity levels but with higher temperatures ( p -values= 0.019 and 0.050). Patients with moderate CH had an increase of up to 0.8 points in their corneal stain score ( p < 0.010). We also found that ozone levels were related to the predicted changes in OSDI and NIBUT.
Conclusion: This study demonstrated the impact of environmental factors on the signs and symptoms of DED and suggests that patients residing in cities with inadequately controlled air pollution can benefit from using ocular lubricants to alleviate their symptoms.
Trial Registration: Trial is registered at clinicaltrials.gov (NCT04702776).
Competing Interests: PMV, GGS, ROJF, SQJ, ASR and OOM are employees of Laboratorios Sophia, S.A. de C.V. The sponsor provided support in the form of salaries for the authors. This does not alter adherence to the Good Publication Practice guidelines for pharmaceutical companies (GPP3) policies on sharing data and materials. The authors report no other conflicts of interest in this work.
(© 2024 Muñoz-Villegas et al.)